Insomnia is among the most common sleep disorders worldwide, and its consequences reach well beyond a rough morning. People with insomnia struggle to fall asleep, to stay asleep through the night, or to wake feeling genuinely refreshed, and the disorder can severely degrade quality of life. Perhaps most importantly, chronic insomnia leaves people substantially more vulnerable to developing anxiety and depression over time, making effective treatment a genuine public health priority. Existing options include cognitive behavioural therapy, which is often recommended as a first-line approach, alongside pharmacological treatments such as antidepressants and antipsychotics, but the success of these interventions varies considerably from patient to patient. It is against this backdrop of imperfect alternatives that interest in medical cannabis has surged.

In clinical settings, medical cannabis is not the same product that consumers encounter in dispensaries. Prescribed cannabis medicines typically involve controlled, laboratory-tested ratios of the two best-known cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), delivered in standardised forms such as tablets, sprays or oils. This standardisation is intended to give clinicians predictable doses and compositions. Anecdotal reports and marketing have long touted cannabis as a sleep aid, and the drug’s sedating reputation has made it an appealing candidate for people desperate for rest. Yet the use of medical cannabis for insomnia remains contentious among sleep researchers and clinicians, and the formal evidence base has been thin.

To resolve that uncertainty, the review team systematically assembled the available randomised evidence. The review included nine studies involving 537 adults aged 18 to 76 who were treated for insomnia. Most of the studies focused on people with primary insomnia rather than insomnia linked to other health conditions, a distinction that matters because comorbid insomnia is often harder to treat and mechanistically different. Eight of the nine trials compared regulated medical cannabis against a placebo, the gold-standard design for determining whether a treatment outperforms expectation effects. The ninth trial took a different approach, comparing medical cannabis against amitriptyline, an antidepressant with sedating properties that is sometimes used off-label for sleep.

The headline result is stark in its modesty. Medical cannabis showed little to no clinically meaningful improvement in sleep quality and satisfaction, total sleep time, or daytime functioning compared with placebo. In other words, on the outcomes that matter most to patients with insomnia, how well they slept and how they functioned during the day, the drug did not demonstrate a clear advantage over an inert comparison. For a treatment whose reputation rests almost entirely on its perceived sleep benefits, this is a significant setback, and it suggests that the anecdotes driving cannabis’s popularity may not survive the scrutiny of controlled trials.

Safety signals added further concern. Participants taking medical cannabis were substantially more likely to experience mild adverse events, such as dry mouth and dizziness, than those receiving placebo. These effects are not dangerous in the way that some drug side effects can be, but they are not trivial for patients weighing whether a treatment is worth taking. Importantly, the review authors note that this safety conclusion was based on a small pool of studies, which means the true rate of adverse events remains imperfectly characterised. Even so, a treatment that shows no clear benefit while increasing the likelihood of side effects faces an unfavourable risk-benefit calculus.

There was one apparent bright spot: medical cannabis somewhat improved quality of life in the pooled analyses. But the reviewers urge heavy caution here. The certainty of this finding was rated very low, and the pooled results were compatible with anything from a slight worsening to a large improvement. That enormous range of plausible effects is a hallmark of unreliable evidence, and it means patients and clinicians cannot reasonably conclude from this dataset that cannabis genuinely enhances quality of life for people with insomnia. The finding is best read as a signal of what better-designed trials might one day examine, rather than as a positive result in its own right.

Why is the evidence so shaky? The review team graded the overall quality and certainty of the evidence as very low to low, and the reasons are instructive for anyone trying to interpret medical research headlines. The underlying studies carried a high risk of bias, meaning flaws in their design or conduct may have distorted their results. Findings were inconsistent between trials, making it hard to generalise from any single study. Sample sizes were small, with the entire review resting on 537 participants across nine trials. The studies also varied considerably in the type of cannabis product used, which limited comparability across trials, since different formulations, cannabinoid ratios and delivery methods can plausibly produce different effects. Perhaps most limiting of all, the longest study followed participants for only 12 weeks, leaving the long-term effects of cannabis treatment for insomnia essentially unknown.

There is also a representativeness problem that the reviewers highlight. The available data were heavily skewed towards younger people and women, who made up 72.66 percent of participants. As a result, the findings may not apply as well to men, to older adults, or to people with comorbid health conditions, groups that represent a large share of real-world patients seeking treatment for sleep problems. Clinicians hoping to use this evidence to guide prescribing for an older patient with multiple health issues will find that the trials simply did not include enough people like them to say anything confident. This gap between trial populations and clinical populations is a recurring weakness in cannabis research, and it is one the review makes impossible to ignore.

The authors’ conclusion is measured but firm: the evidence remains weak and uncertain, and higher-quality research is needed before medical cannabis can be recommended for insomnia. Dr Lucia Varela, lead author of the study from the University of Manitoba in Canada, emphasised that the research currently available is not sufficient to reliably answer whether medical cannabis helps people with insomnia, adding that this does not mean the treatment is ineffective, but that based on current evidence no reliable conclusions about its effectiveness can be drawn for the general population. Dr Luis Garegnani, senior author from the Universidad Hospital Italiano de Buenos Aires in Argentina, advised that rather than viewing the findings as an endorsement or a rejection of medical cannabis, clinicians and patients should recognise the uncertainty and consider individual circumstances while better evidence is generated. All authors declared no commercial or non-commercial conflicts of interest relevant to the review. For now, the message for the millions of people struggling with sleepless nights is not that cannabis cannot work, but that no one yet knows whether it does, and the only honest response to that uncertainty is more rigorous science.

Subject of Research: Medical cannabis as a treatment for insomnia

Article Title: Insufficient evidence to back medical cannabis for insomnia

Article References: Insufficient evidence to back medical cannabis for insomnia. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: medical cannabis, insomnia, Cochrane review, sleep quality, THC, CBD, systematic review, placebo, evidence quality, sleep disorders, clinical trials, daytime functioning

The underlying clinical trial, registered as NCT05597020, enrolled 60 adults aged 55 or older who had endured insomnia symptoms for at least three months, scored 13 or higher on the Insomnia Severity Index, and reported at least three nocturnal voids per night. Participants were randomized in a one-to-one ratio to receive either daridorexant 50 mg or placebo for four weeks, then crossed over to the other treatment after a washout period of 14 to 21 days. This crossover design carries a distinct methodological advantage: each participant serves as their own control, which minimizes inter-participant variability and allows direct within-person comparisons of how the two treatments felt in everyday life.

What makes the new publication unusual is its commitment to the qualitative dimension of the patient experience. Alongside the validated questionnaires that formed the trial’s quantitative backbone, patients were asked open-ended, free-text questions at baseline and at the end of each treatment period. At screening, they described how insomnia and nocturia had impacted their daily lives before the study began. After each treatment month, they were asked how that impact had changed while taking the study medication. The replies were pooled into two groups, one containing responses from patients who had received daridorexant during either treatment period and the other containing responses from patients who had received placebo, and the analysis team remained blinded to treatment assignment until the coding was complete.

The analytic machinery behind the study was deliberately rigorous. Using MAXQDA version 2024, a qualitative data analysis platform, a trained analyst coded every response according to a structured codebook developed under a predefined Qualitative Analysis Plan. The codebook captured mentions of sleep, nocturia, and their impacts on physical, emotional, and cognitive functioning, activities of daily living, professional life, and relationships, with sub-codes recording whether patients described improvement, stability, worsening, or mixed change. Crucially, the themes emerged inductively from the data rather than being imposed by prior hypotheses, and no automated or AI-assisted coding was used. Regular meetings between the analyst, the research lead, and a scientific advisor resolved ambiguities, and all analytic decisions were logged to maintain consistency across the dataset.

The baseline picture that emerged was bleak and remarkably consistent. Of the 59 patients who replied at baseline, 68 percent described sleep problems, including difficulty falling asleep, staying asleep, and waking too early, while 37 percent described nocturia symptoms such as frequent nighttime voiding or incontinence. Two-thirds of replies referenced sleep issues and one-third referenced nocturia, suggesting that for these patients the insomnia itself was the more bothersome burden. But the damage extended far beyond the bedroom. Fully 83 percent of respondents commented on impacts on their lives, with 61 percent reporting negative effects on physical functioning, citing fatigue, tiredness, low energy, weakness, dizziness, and grogginess, and 52.5 percent reporting emotional tolls including frustration, irritability, stress, and nervousness. One in five described impaired cognition, and work and social life suffered as well.

After four weeks on treatment, the contrast between daridorexant and placebo was striking. Among patients taking daridorexant, 87 percent reported improvement in their sleep, compared with just 50 percent on placebo, a difference the researchers found highly significant with a p value of 0.0011. Only 10 percent of daridorexant patients said their sleep problems were unchanged, versus 40 percent of placebo patients. The nocturia findings were, if anything, more dramatic: 79 percent of patients on daridorexant reported improvement in their nighttime voiding, compared with 32 percent on placebo, a highly significant difference with a p value of 0.0013. These patient-perceived improvements align closely with the trial’s quantitative results, which showed that daridorexant increased subjective total sleep time by roughly 21 minutes and reduced nocturnal voids by an average of 1.5 episodes per night.

The benefits rippled outward into daily functioning. Improvements in quality-of-life impacts were reported by 73.7 percent of daridorexant patients who commented on impacts, compared with 46.7 percent of placebo patients. Physical functioning showed the largest gains, with 52.6 percent of daridorexant patients reporting improvement versus 26.7 percent on placebo. Cognitive functioning, activities of daily living, and emotional functioning also improved more frequently under daridorexant, with placebo patients showing no reported cognitive improvements at all. Patients described feeling less fatigued, more able to concentrate, and better equipped to manage ordinary routines that fragmented sleep had made exhausting.

Why would a sleep drug ease the urge to urinate at night? The authors offer two complementary hypotheses. The first is mechanical: by lengthening sleep duration and shortening long awakenings, daridorexant simply gives patients fewer opportunities to notice a full bladder, an explanation supported by earlier work showing that behavioral treatment of insomnia alone reduced self-reported nocturnal voids in older adults. The second is neurobiological and arguably more intriguing. The orexin system, best known for stabilizing wakefulness, also appears to influence micturition. Animal studies have shown that orexin-A activates the micturition reflex, and that blocking orexin 2 receptors restores abnormal bladder markers in models of overactive bladder. In humans, orexin antagonists may increase bladder capacity by prolonging the interval between bladder contractions. Consistent with this, orexin agonists given to people with narcolepsy have produced increased urinary urgency and frequency as expected on-target effects, the mirror image of what antagonists appear to do.

The study’s authors argue that these findings fill a genuine gap in sleep medicine. A systematic review of qualitative insomnia research identified only 22 published studies, many of which actually relied on quantitative methods, and concluded that well-conducted qualitative work in the field remains scarce compared with areas such as depression. Free-text responses complement structured patient-reported outcome measures by adding contextual depth, capturing experiences such as non-restorative sleep and mood disturbance that objective measures may miss. The longitudinal design of the survey, with baseline responses collected before treatment, also avoids the recall bias inherent in asking patients at study exit to reconstruct how they felt months earlier. And because patients were blinded to treatment and the analysts were blinded too, expectancy effects were constrained as far as the design allows.

Limitations remain, and the authors are candid about them. Responses summarized an entire month retrospectively, inviting recall bias, and the level of detail varied considerably across patients. A few replies were missing or uninterpretable, and subjective free-text data can still be shaped by placebo and expectancy effects even in a blinded crossover. Coding inevitably involves some interpretive judgment, mitigated here by a predefined analysis plan, blinded coding, and documented quality checks. The study also relied on patient history rather than polysomnography to exclude other sleep disorders. Even so, the message is compelling: patients with moderate to severe insomnia and clinically meaningful nocturia reported broad damage to their physical, emotional, and cognitive lives, and daridorexant 50 mg consistently elicited more positive patient-reported change than placebo across sleep, voiding, and daily functioning. As clinical trials increasingly seek to center the patient’s voice, this study offers a template for letting patients describe, in their own words, what treatment actually feels like.

Subject of Research: Qualitative patient-reported outcomes of daridorexant treatment in adults with chronic insomnia and comorbid nocturia

Article Title: Capturing the Patient Voice: Qualitative Assessment of Daridorexant’s Impact on Patients with Insomnia and Comorbid Nocturia from a Randomized, Placebo-Controlled Crossover Trial

Article References: Arnaldi, D., Bliwise, D. L., Alpan, D., Koochaki, P., Meinel, M., Olivieri, A., Rowles, R., Satapathy, A., & Lederer, K. (2026). Capturing the Patient Voice: Qualitative Assessment of Daridorexant’s Impact on Patients with Insomnia and Comorbid Nocturia from a Randomized, Placebo-Controlled Crossover Trial. Advances in Therapy. https://doi.org/10.1007/s12325-026-03803-0

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03803-0

Keywords: daridorexant, insomnia, nocturia, dual orexin receptor antagonist, patient-reported outcomes, qualitative research, crossover trial, sleep medicine, quality of life, orexin system, placebo-controlled trial, daytime functioning